EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Syndecan-1 as a biomarker of endothelial glycocalyx injury in sepsis: a meta-analysis of associations with shock, organ complications and mortality

Syndecan-1 als Biomarker für Schäden am endothelialen Glykokalyx bei Sepsis: Metaanalyse zu Schock, Organkomplikationen und Mortalität

Dongling Xu, Chengshu Dong, Zifang Zhao, Siyuan Hou iD

Postgraduate Medical Journal · 21.08.2026 · 102 (1211) · 867-875

DOI: 10.1093/postmj/qgag053 ↗

Auf einen Blick

In 29 Studien mit 4985 Teilnehmenden waren Syndecan-1-Spiegel bei Sepsis höher als ohne Sepsis. Höhere Werte zeigten sich auch bei Nichtüberlebenden, septischem Schock, AKI und DIC.

Fragestellung

Wie ist Syndecan-1 bei Sepsis mit Krankheitsausprägung, Organkomplikationen und Prognose assoziiert, und welchen Zusatznutzen hat es gegenüber konventionellen Sepsismarkern?

Methode

Systematische Übersichtsarbeit und Metaanalyse nach PRISMA; Analyse mit Review Manager 5.3; SMD und 95 %-KI; Subgruppen nach Sepsis-Definition und Sensitivitätsanalysen ohne Studien mit schwerem/kritischem ROBINS-I-Bias.

Ergebnisse

29 Studien mit 4985 Teilnehmenden, davon 3902 mit Sepsis. Syndecan-1 bei Sepsis höher als ohne Sepsis: SMD 1,16 (95 %-KI 0,86–1,47; p < 0,00001). Auch bei Nichtüberlebenden, septischem Schock, AKI und DIC höher (alle p < 0,00001).

Einschränkungen

Schwere oder kritische ROBINS-I-Bias in 9 Studien; keine weiteren Limitationen genannt.

Schlussfolgerung der Autor:innen

Erhöhtes Syndecan-1 weist auf eine Störung des endothelialen Glykokalyx bei Sepsis hin und ist mit schlechterer Prognose, septischem Schock und Organfunktionsstörungen verbunden. Es ergänzt Lactat, Procalcitonin und CRP.

Kernaussagen

  • Syndecan-1 war bei Sepsis höher als ohne Sepsis.
  • Auch bei Nichtüberlebenden, Schock, AKI und DIC erhöht.
  • Als Ergänzung zu Lactat, PCT und CRP, nicht als Ersatz.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Metaanalyse in der Zeitschrift Postgraduate Medical Journal, online erschienen am 22.04.2026. Verfasst von Dongling Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Unit, The People's Hospital of Liaoning Province, NO. 33 Wenyi Road, Shenhe District, Shenyang, Liaoning Province 110016, China. Hauptthemen laut MEDLINE: Syndecan-1, Glycocalyx, Sepsis, Shock, Septic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Science Foundation of Liaoning Province of China.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This meta-analysis aimed to assess syndecan-1 as a biomarker reflecting endothelial glycocalyx injury in sepsis, investigate its correlation with disease severity, organ complications and clinical prognosis, and clarifies its complementary value relative to conventional sepsis biomarkers.

Design

A systematic review and meta-analysis conducted in accordance with PRISMA guidelines. Data analysis was performed using Review Manager 5.3, with standardized mean differences (SMD) and 95% confidence intervals (CI) calculated. Subgroup analyses were stratified by sepsis definitions (Sepsis 1.0/2.0 vs. 3.0), and sensitivity analyses were performed by excluding studies with serious or critical ROBINS-I bias. Patients A total of 29 studies involving 4985 participants (3902 with sepsis) were included. Main Outcome Measures Circulating syndecan-1 levels in sepsis patients versus non-sepsis controls, survivors versus non-survivors, and patients with septic shock, acute kidney injury (AKI) and disseminated intravascular coagulation (DIC).

Results

Syndecan-1 levels were significantly higher in sepsis patients than non-sepsis [SMD = 1.16, 95% CI (0.86, 1.47), p < 0.00001]. Non-survivors had significantly elevated levels compared with survivors, and higher levels were also observed in patients with septic shock, AKI and DIC (all p < 0.00001). Subgroup analyses yielded consistent findings across different sepsis definitions, and sensitivity analyses excluding 9 high-bias studies confirmed the robustness of the results.

Conclusion

Elevated syndecan-1 indicates endothelial glycocalyx disruption in sepsis, and is closely linked to worse prognosis, septic shock and organ dysfunction. As a complementary biomarker to lactate, procalcitonin and C-reactive protein, it improves multi-domain sepsis risk stratification and supports individualized resuscitation and endothelial-protective intervention research. Key messages What is already known on this topic? Syndecan-1 is a marker of endothelial glycocalyx degradation and has been linked to sepsis severity. However, its precise association with prognosis and complications remains unclear, and its clinical value relative to traditional sepsis biomarkers (lactate/PCT/CRP) has not been systematically clarified, necessitating a meta-analysis to quantify its clinical relevance and complementary role. What this study adds This study confirms that syndecan-1 levels are significantly elevated in sepsis, especially in severe cases, non-survivors, and patients with AKI or DIC, validating its role as a specific biomarker of sepsis-associated endothelial glycocalyx injury. Importantly, it clarifies that syndecan-1 is not a replacement for traditional biomarkers but a complementary indicator that captures the endotheliopathy domain unmeasured by lactate/PCT/CRP. Its lack of specificity for sepsis limits its utility as a standalone diagnostic biomarker, but it provides incremental prognostic value for risk stratification. How this study might affect research, practice, or policy Syndecan-1 may serve as a prognostic marker for endothelial dysfunction in sepsis and a stratification tool for identifying patients at high risk of capillary leak and fluid resuscitation-related adverse outcomes. It should be used alongside other biomarkers to inform personalized resuscitation strategies. This meta-analysis provides the most comprehensive quantitative evidence to date for the integration of “glycocalyx-friendly” management into future sepsis research and clinical guidelines, and guides the design of forthcoming trials targeting endothelial barrier protection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Syndecan-1GlycocalyxSepsisShock, SepticAcute Kidney InjuryHumansBiomarkersPrognosisDisseminated Intravascular CoagulationEndothelium, Vascular

Stichwörter der Autor:innen

biomarker; mortalitymeta-analysissepsisseptic shocksyndecan-1

Substanzen

Syndecan-1BiomarkersSDC1 protein, human

Autor:innen und Institutionen

  • Intensive Care Unit, The People's Hospital of Liaoning Province, NO. 33 Wenyi Road, Shenhe District, Shenyang, Liaoning Province 110016, China.

ORCID-Profile: Siyuan Hou

Förderung

  • National Science Foundation of Liaoning Province of China

Zitieren

APA

Xu, D., Dong, C., Zhao, Z., & Hou, S. (2026). Syndecan-1 as a biomarker of endothelial glycocalyx injury in sepsis: a meta-analysis of associations with shock, organ complications and mortality. Postgraduate Medical Journal, 102(1211), 867-875. https://doi.org/10.1093/postmj/qgag053

Vancouver

Xu D, Dong C, Zhao Z, Hou S. Syndecan-1 as a biomarker of endothelial glycocalyx injury in sepsis: a meta-analysis of associations with shock, organ complications and mortality. Postgraduate Medical Journal. 2026;102(1211):867-875. doi:10.1093/postmj/qgag053

BibTeX
@article{Xu2026,
  author = {Xu, Dongling and Dong, Chengshu and Zhao, Zifang and Hou, Siyuan},
  title = {Syndecan-1 as a biomarker of endothelial glycocalyx injury in sepsis: a meta-analysis of associations with shock, organ complications and mortality},
  journal = {Postgraduate Medical Journal},
  year = {2026},
  volume = {102},
  number = {1211},
  pages = {867--875},
  doi = {10.1093/postmj/qgag053}
}
Kostenlos starten →